The mRECIST and dermatologic adverse events (AEs) can be used to assess the patient response to transarterial chemoembolization (TACE) and/or sorafenib for hepatocellular carcinoma (HCC). Here, we aimed to combine the two criteria to stratify the prognosis in patients with unresectable HCC receiving TACE plus sorafenib (TACE-S). In total, 176 consecutive HCC patients treated with TACE-S were enrolled. CT scans and laboratory tests were conducted pretreatment (at baseline, 5-7 days before the TACE-S) and post-treatment (at 1, 2 and 3 months). The radiological response was assessed according to mRECIST. Sorafenib-related AEs were recorded every 2 weeks after oral administration, and patients with dermatologic AEs of Grade 2 or more were defined as dermatologic responders. The earliest time at which mRECIST and dermatologic responses correlated with survival was 2 months after therapy. The mRECIST-dermatologic AE combination assessment stratified patients into three different prognoses; responders on both assessments exhibited the longest median overall survival (OS), followed by responders on one assessment and non-responders on both assessments (30.5, 17.4 and 8.3 months, respectively; p < 0.001). Achieving the highest C-index, the mRECIST-dermatologic AE combination showed better performance in predicting survival than either mRECIST or dermatologic AEs alone. Furthermore, the mRECIST-dermatologic AE combination remained a significant predictor of OS, even when the patients were stratified according to the BCLC stage, ECOG score or alpha-fetoprotein (AFP) value. This study showed that the combination of mRECIST response and dermatologic AEs is superior to either criterion used alone for predicting the survival of HCC patients treated with TACE-S. 
TACE therapy by decreasing TACE-induced angiogenesis, combining TACE with sorafenib (TACE-S) might make a difference in HCC treatment. 4 On the other hand, according to the global HCC BRIDGE study, patients in China have a higher tumor load, with a mean tumor diameter of 6.7 cm, which is almost double that found in other countries. 5 The survival benefit may be modest when TACE or sorafenib monotherapy is administered. Therefore, TACE-S may be the alternative choice of treatment for patients with unresectable HCC. 6 Indeed, a series of studies have reported the survival benefit conferred by TACE-S for HCC. [7] [8] [9] [10] [11] The modified Response Evaluation Criteria in Solid Tumors (mRECIST) plays a pivotal role in the treatment response evaluation. 12 Several studies, including our previous work, have reported that mRECIST response is an independent predictor for overall survival (OS) after TACE and/or sorafenib therapy. [13] [14] [15] [16] [17] However, using the mRECIST has limitations: the reproducibility of interobserver measurements has not been adequately assessed, and the proposed cut-off values used to define objective responses may not always accurately predict tumor response. 18, 19 Therefore, evaluating the efficacy of TACE-S by mRECIST alone is not sufficient. Interestingly, several studies, including our recent article, have confirmed that the dermatologic adverse events (AEs) that arise during sorafenib treatment can be used as an early and significant prognostic factor of survival. [20] [21] [22] [23] Because mRECIST can be used to assess the primary tumor response after locoregional or systemic therapy and dermatologic AEs can reflect the efficacy of systematic sorafenib treatment, we postulated that combining the mRECIST response with dermatologic AEs may comprehensively and accurately predict survival among HCC patients treated with TACE-S. Therefore, we aimed to combine these two criteria to evaluate the response to TACE-S treatment of patients with unresectable HCC.
Material and Methods

Study population
This was a retrospective study in which patients with unresectable HCC who had been treated with TACE-S between January 2009 and December 2013 were consecutively enrolled. All patients (aged 18 years or older) were diagnosed by means of histology or dynamic imaging scan according to EASL or AASLD diagnostic criteria. 2, 3 Only patients who met all of the following criteria were included in this study: well-preserved liver function with Child-Pugh class A or B (<8) and Eastern Cooperative Oncology Group (ECOG) score 0-1. At baseline measurement, all patients must have had at least one target lesion with a diameter of at least 1 cm. We also excluded patients who had any of the following conditions: (i) extrahepatic disease, (ii) complete occlusion of the entire portal venous system, (iii) second primary malignancy, (iv) curative therapy after TACE-S, (v) administered other target agents or received a transjugular intrahepatic portosystemic shunt, (vi) sorafenib discontinuation because of patient noncompliance or an elapsed time between sorafenib administration and TACE procedure of >1 month, (vii) infiltrative lesions not suitable for imaging assessment and/or (viii) survival time <3 months. The study was approved by our hospital's institutional review board.
Treatment TACE-S treatment was recently described in detail. 17 For TACE treatment, we followed the "on-demand" strategy. Repeated TACE was implemented upon confirmation of a viable tumor or local and/or distant intrahepatic recurrences, provided that the patient's medical condition permitted the treatment. Sorafenib was administered as a dose of 400 mg twice daily and was not interrupted during TACE therapy. Patients were encouraged to continue sorafenib treatment as long as the AEs remained manageable. Dose reduction was allowed upon the occurrence of intolerable AEs or the deterioration of liver function. Once dermatologic AEs occurred, urea-based creams were routinely used.
Follow-up
All patients underwent physical examination; laboratory tests, including the alpha-fetoprotein (AFP) level, a liver function panel, and hepatitis serologic tests; contrast-enhanced computed tomography (CT); and a metastatic work-up 5-7 days before TACE-S treatment. Follow-up contrast-enhanced CT was performed every 4-6 weeks to assess tumor response and guide timely decision making regarding subsequent therapies. Tumor response was assessed according to the overall mRE-CIST. 24 The measurement of up to 2 target lesions per organ was adopted for response evaluation. 25, 26 Patients exhibiting complete response (CR) or partial response (PR) were categorized as mRECIST responders, whereas those with stable disease (SD) or progressive disease (PD) were classified as mRECIST nonresponders. Response evaluation was performed
What's new? Two tests are especially useful in predicting survival after standard treatment for intermediate or advanced hepatocellular carcinoma (HCC). These are the mRECIST test and the measurement of dermatologic adverse events (AEs). However, both have limitations. In this study, the authors combined the tests in order to assess prognosis. They found that the combined results yielded a more accurate prediction of post-treatment survival than either criterion alone. They also concluded that dermatologic AEs should be considered as signs of efficacy rather than simply as negative effects of treatment.
by two of four experienced clinicians (G. Han, W. Bai, W. Wang and Y. Zhao) who were blinded to the conditions of the study. When a discrepancy occurred in the response assessment, the images were reviewed carefully by all four clinicians until consensus was reached. The AE grade was determined according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0 (Bethesda, MD) and recorded. AEs were evaluated every 2 weeks by two independent physicians (W. Bai and G. Han). Consistent with previous studies, grade 2 was selected as the cut-off. 21, 23, 27 We defined patients with skin toxicity Grade 2 as dermatologic responders and patients with skin toxicity < Grade 2 as dermatologic nonresponders.
Statistical analysis
OS was defined as the time from the start of TACE-S to death, the date of loss to follow-up, or August 31, 2014. Survival was estimated using the Kaplan-Meier method, and differences in survival between groups were assessed by the logrank test. Continuous variables are expressed as the means 6 standard deviation. Categorical variables are presented as frequencies and percentages. The predictive value of each variable for OS was evaluated via univariate Cox analysis. To determine the earliest time at which the mRECIST and dermatologic AEs could be used independently to predict HCC prognosis, we built three multivariate Cox proportional regression models using baseline characteristics with p < 0.05 according to the univariate analysis and the mRECIST response and dermatologic AE data assessed at 1, 2 and 3 months after TACE-S. We then compared the C-index to evaluate the discriminatory abilities of mRECIST alone, dermatologic AEs alone and the two in combination to predict OS. All statistical tests were two-tailed, and p < 0.05 indicated a significant difference.
Results
Patient characteristics
Of the 427 patients initially recruited, 251 were excluded for having a Child-Pugh score 8 (n 5 24); an ECOG score 2 (n 5 5); sorafenib discontinuation because of patient noncompliance or an elapsed time between sorafenib administration and TACE procedure >1 month (n 5 62); curative therapy after TACE-S (n 5 14); the administration of other target agents or a transjugular intrahepatic portosystemic shunt (n 5 17); infiltrative lesions not amenable to imaging assessment (n 5 34); or extrahepatic spread, other coexisting cancers, or a predicted survival <3 months (n 5 95). Ultimately, 176 HCC patients were enrolled in this study. The detailed baseline characteristics of these patients are summarized in Table 1 . The patient population consisted of 152 (86.4%) men and exhibited an age range of 26-83 years (median, 51 years). One hundred fifty-one (85.8%) patients presented with hepatitis B, and 167 (94.9%) patients were classified as Child-Pugh A. Branch portal vein tumor 
Response assessment according to mRECIST response and dermatologic AEs
One month after TACE-S (median, 1.1 months; range: 0.7-1.4), 151 patients receiving one TACE session underwent imaging examination; of these patients, 83 were mRECIST responders, and 68 were nonresponders. Two months after TACE-S (median, 2.3 months; range: 1.8-2.5), of the 161 patients who were available for radiological evaluation, 92 were mRECIST responders, and 69 patients non-responders. When analyzed three months after TACE-S (median, 3.1 months; range: 2.8-3.8), 17 patients (9.7%) were excluded because of the absence of imaging data; 71 patients were mRECIST responders, and 88 patients were nonresponders. The median time of dermatologic AE onset was 17 days (range: 3-110 days). With respect to dermatologic AEs, 77 (43.8%), 94 (53.4%) and 100 (56.8%) patients were defined as dermatologic responders 1, 2 and 3 months after TACE-S, respectively.
Univariate and multivariate cox analysis
Baseline characteristics, including the ECOG score, branch PVTT, tumor size, AFP, total bilirubin (TBIL) and aspartate transaminase (AST) were significantly associated with OS in the univariate analysis (p < 0.05) ( Table 2) . Including all the significant baseline variables mentioned earlier together with the mRECIST and dermatologic responses assessed at 1, 2 and 3 months after TACE-S, we built three multivariate Cox proportional regression models. The multivariate models indicated that in addition to the baseline AFP value, TBIL value, ECOG score and branch PVTT, dermatologic AEs and mRECIST response assessed at 2 and 3 months after TACE-S were independent prognostic factors for survival (Table 3) , respectively, at 3 months after TACE-S therapy. The earliest time at which the response could be accurately evaluated was 2 months after therapy. At that time point, the mRECIST responders exhibited improved OS compared with the nonresponders (median OS, 21.5 vs. 12.1 months, respectively; p < 0.001) (Fig. 1a) . Additionally, statistically significant differences in OS were found between dermatologic responders and nonresponders (median OS, 23.2 vs. 10.3 months, respectively; p < 0.001) (Fig. 1b) .
Prognosis stratification according to mRECIST response and dermatologic AEs
On the basis of the outcomes of the mRECIST response and dermatologic AEs evaluated at 2 months after TACE-S, four groups were defined: responders on both assessments, responders on 
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mRECIST alone, responders on dermatologic AEs alone, and nonresponders on both assessments. No significant differences in the median survival were detected between the responders on mRECIST alone and the responders on dermatologic AEs alone (p 5 0.971) (Fig. 1c) . Thus, three groups were created: responders on both assessments, responders on either assessment alone, and nonresponders on both assessments. The median survival durations of the three groups were 30.5, 17.4 and 8.3 months, respectively (p < 0.001) (Fig. 1d) . Compared with nonresponders on both assessments, the HRs for the OS of responders on either assessment and responders on both assessments were 0.428 (95% CI 0.266-0.690, p < 0.001) and 0.194 (95% CI 0.110-0.341, p < 0.001), respectively, and the significant risks of these groups decreased by 57.2% and 80.6%, respectively. 
Prognostic value comparison
The C-index values for mRECIST, dermatologic AEs, and their combination were 0.60 (95% CI 0.55-0.65), 0.61 (95% CI 0.57-0.66) and 0.65 (95% CI 0.59-0.71), respectively, demonstrating that using the two criteria in combination resulted in better discrimination than either variable alone.
The mRECIST-dermatologic AE combination assessment can predict the OS in subgroups
The mRECIST-dermatologic AE combination remained a significant predictor of OS, even when the patients were stratified according to the relevant baseline clinical characteristics:
Barcelona Clinic Liver Cancer (BCLC) stage, ECOG score and AFP value. Notably, in BCLC B patients, the median OS values of responders on both assessments, responders on either assessment, and non-responders on both assessments were as follows: not reached, 26.8 and 13.9 months, respectively (p < 0.001) (Fig. 2a) . A similar trend was observed among BCLC C patients (Fig. 2b) . Additionally, the mRECISTdermatologic AE combination assessment performed equally well in subgroups of ECOG 0 and 1. The median OS values of the three groups of responders were as follows: not reached, 21.5 months and 9.7 months, respectively, for ECOG 0 patients (p < 0.001) (Fig. 2c ) and 18.7, 12.2 and 8.1 months, respectively, for ECOG 1 patients (p 5 0.001) (Fig. 2d) . Finally, the mRECIST-dermatologic AE combination assessment also achieved prognostic stratification in subgroups with AFP 200 and AFP >200. The median OS values of responders on both assessments, responders on either assessment, and nonresponders on both assessments were as follows: 39.5, 24.0 and 10.7 months, respectively, for patients with AFP 200 (p 5 0.001) (Fig. 2e ) and 20.7, 11.9 and 7.4 months, respectively, for patients with AFP >200 (p < 0.001) (Fig. 2f) .
Sensitivity analysis
We conducted a sensitivity analysis to investigate whether the results could be biased because of the loss of some patients to follow-up. Indeed, 25 (14.2%), 15 (8.5%) and 17 (9.7%) patients did not undergo follow-up CT scans at 1, 2 and 3 months, respectively. The Kaplan-Meier survival curves (Fig. 1 , Supporting Information) revealed no statistically difference in OS among the three groups when analyzed at 1 month after therapy, and the patients who were lost to the 2-and 3-month CT scans had the worst OS. Comparisons of baseline variables among the three groups revealed that none of the factors differed significantly between groups, except for age, when analyzed at 1 month after therapy; additionally, the patients lost to the 2-and 3-month CT scans had larger tumor sizes and higher proportions of BCLC C, ECOG 1 and PVTT (Tables 1-3 , Supporting Information). Thus, whereas patients may have been lost to the 1-month CT scan because they were older and 1 Tumor size is expressed as the median (range), mean 6 SD or size (percentage). 2 The radiological responses were assessed according to mRECIST or EASL criteria. 3 Total sum of the diameters of HCC lesions.
exhibited relatively poor compliance, those lost to the 2-and 3-month scans exhibited deteriorating conditions, which were associated with worse OS. When the missing radiological data at 2 months after therapy was replaced with the latest data collected (1 or 3 months), dermatologic AEs and mRECIST response assessed at 2 months after TACE-S were still independent prognostic factors for survival. The C-index values for mRECIST, dermatologic AEs, and the two in combination were 0.61, 0.61 and 0.66, respectively. The mRECIST-dermatologic AE combination remained a statistically significant predictor of OS when the patients were stratified according to BCLC stage, ECOG score and AFP value. These results were consistent with the analysis with the missing values.
Discussion
In this study, we combined the mRECIST response and dermatologic AEs to stratify the prognoses of HCC patients receiving TACE-S. Our study showed that with the highest C-index, the combination of mRECIST response and dermatologic AEs showed better performance in predicting survival than either criterion used alone. Additionally, responders on both assessments had the longest median OS, followed by responders on either assessment and nonresponders on both assessments. More importantly, the mRECIST-dermatologic AE combination assessment remained significant even after patients were stratified according to BCLC stage, ECOG score and AFP value.
To better predict the prognosis of HCC patients, we should account for their baseline characteristics, such as tumor stage, liver function and physical status, and their responses to therapy. 28 As shown in Table 4 , Supporting Information, the baseline variables combined with treatment response exhibited the highest Harrell's C and the best prognostic value. However, baseline characteristics alone are generally used to predict patient prognosis and guide decision making regarding the initial treatment. In contrast, the responses to therapy are used to judge whether patients may continue to benefit from the current therapy and guide future treatment. In this study, we selected relatively homogenous HCC patients with preserved liver function, good physical status, patent main portal vein and no extrahepatic spread as the best candidates for TACE-S therapy and focused on the significance of their treatment responses.
The mRECIST exhibited a satisfactory capability to predict survival at early time points in patients with HCC, providing us with intuitional information not only on the tumor size, morphology, and blood supply but also the liver status. Consequently, this assessment played a pivotal role in determining efficacy and clinical decision making. Recently, a correlation between worsening selective sorafenib-related AEs and improved outcome was reported. Indeed, AEs, such as hand-foot-skin reaction (HFSR), rash, hypertension and diarrhea, have been associated with positive results. 21, [29] [30] [31] Of these AEs, dermatologic AEs are more common and specific for sorafenib treatment than the others and are also simple to accurately identify and evaluate, facilitating their clinical application by both clinicians and patients. Furthermore, dermatologic AEs can be conveniently assessed and continuously recorded in detail, which is of great utility. Our study indicated that the combination of these two assessments was better than either alone at predicting survival and provided more information for patients and clinicians. Therefore, we suggest incorporating mRECIST and dermatologic AEs into the response assessment system. Currently, the clinical outcomes reported in studies evaluating the efficacy of TACE-S are widely varied. 7, 9, 11, 32, 33 Furthermore, the significant differences found in these studies can be attributed to ignorance of the response to therapy. Because of the lack of reliable biomarkers for sorafenib use, dermatologic AEs related to sorafenib have become widely recognized as surrogate markers for efficacy in patients with HCC. [20] [21] [22] The prognostic value of these dermatologic AEs was also confirmed in our very recent multicentre clinical study of 606 HCC patients, which demonstrated that sorafenib-related dermatologic AEs may be used as clinical indicators to identify responders to sorafenib and those who are more likely to benefit from TACE-S treatment. 23 Indeed, patients who develop dermatologic AEs might constitute the ideal population in whom the addition of sorafenib would work. Conversely, patients without dermatologic AEs may fail to benefit from sorafenib. Additionally, TACE-S might have a greater benefit among patients living in areas with high tumor burden, such as China. Indeed, an inverse correlation between the tumor burden and radiological response has been reported. 34 As summarized in Table 4 , which presents the tumor burden and radiological response to TACE for intermediate-stage HCC in different countries, the median tumor diameter of TACE-treated patients in China was 8 cm, 35 which is almost double those found in Japan, South Korea, Europe and North America. Consequently, the response and CR rates of patients in China were nearly 58% and 15%, respectively, which were extremely low as compared to those observed in other countries. To improve the response or CR rate of patients following TACE, combining TACE with other locoregional therapies or systemic treatments may be an option. TACE-S could be the optimal approach for HCC patients with high tumor burden who failed to achieve CR after TACE alone. Additionally, responders on both mRECIST and dermatologic AEs may receive more benefit from TACE-S therapy.
Our study demonstrated that the mRECIST response at 2 months after TACE-S can predict improved survival. This finding differed from that determined in our previous work, which showed that mRECIST results at 3 months after TACE-S correlated well with survival. 17 At least two explanations exist for this observation. First, in the current study, we considered the factors influencing patient outcomes more thoroughly, and dermatologic AEs were considered as an important variable. Second, and more importantly, the compositions of the two studies differed, with the present study excluding patients with extrahepatic spread, who always also exhibited higher tumor load and large or multifocal HCC; these patients may require a longer treatment duration to show an effect.
The present study is associated with particular strengths worth noting. First, in contrast to previous studies that chiefly analyzed the prognostic value of the best response during TACE or sorafenib therapy, in which a time lag bias resulted from the different intervals between the treatment and the best acquired response, our present study conducted a multiple time-point evaluation and found that two months after TACE-S was the earliest time at which the mRECIST and dermatologic responses correlated well with survival. Second, our study showed that responders on both assessments who had the longest median OS independent of BCLC stage, ECOG status and AFP values may be potential candidates for TACE-S treatment. In contrast, nonresponders on both assessments, who had the worst median OS, may not be suitable for TACE-S therapy. Responses to therapy can be used to indicate current treatment and can be useful tools for guiding further treatment.
Nevertheless, this study also possesses several limitations. First, this was a single-institution retrospective study; therefore, the strength of our conclusions is limited by the retrospective nature of the results. Second, other variable such as the AFP response in the previous studies, [36] [37] [38] was not included in the response assessment. The study population of these studies was patients with high AFP value and the patients with low AFP values were excluded from analysis. Furthermore, in our recent study, we found that the AFP response in patients with baseline AFP levels >20 ng/ml after combination therapy was the independent predictors of survival. 39 But in this study, AFP response does not add to the models. Third, the evaluation of mRECIST and AEs may be biased because of investigator-independent factors. However, every evaluation was assessed by at least two clinicians independently, and when there was a discrepancy, a consensus was reached by a panel of clinicians to lessen the error caused by the observers.
In conclusion, the combination of mRECIST response and dermatologic AEs, which was superior to either used alone, is clinically useful to predict the survival of patients with unresectable HCC treated with TACE-S. Responders on both assessments may be potential candidates for TACE-S treatment, and nonresponders on both assessments, who had the worst median OS, may not be suitable for TACE-S therapy. Further studies are needed to confirm our findings in independent external populations.
